skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Global Search Configuration

Refine Results

Clear All

Specialism

Show More

Resources

Show More

Products

Show More

Show More

10 Total results for product and free and sample content found

Datamonitor Healthcare

Immuno-Oncology Overview

By Colin White, Robert Jeng & Jolene Lau 28 Jul 2022

Immuno-Oncology Overview

This is an overview of the field of immuno-oncology and the various immuno-oncology classes. Immuno-oncology is one of the most promising and fastest growing areas of cancer research, as well

Topic immuno-oncology

Datamonitor Healthcare, Biomedtracker, Pharma...

2019 Q3 Outlook Webinar

By Hardik Patel 16 Jun 2022

Informa Pharma Intelligence presents an essential, free session during which industry analysts present their data-driven views about what to expect during the third quarter of 2019. 

Topic immuno-oncology Infectious Diseases

Scrip

BMS' Opdivo Approval In CRC Overshadowed By Keytruda Dominance

02 Aug 2017

BMS' Opdivo Approval In CRC Overshadowed By Keytruda Dominance

The US FDA has approved BMS' Opdivo for previously treated patients with some forms of colorectal cancer, however direct competition from Merck's Keytruda may limit its success.

Topic immuno-oncology Cancer

Scrip

PD-1 Data Emerges In Cervical Cancer

By Lucie Ellis 26 Jul 2017

PD-1 Data Emerges In Cervical Cancer

Leading immunotherapy agents are beginning to report early-stage data from monotherapy and combination trials in advanced cervical cancer – a treatment area with very few approved options.

Topic Cancer immuno-oncology Research & Development Strategy

Scrip

NSCLC Momentum Goes To Merck And Roche, Bodes Well For Combinations

By Joseph Haas 13 Feb 2017

NSCLC Momentum Goes To Merck And Roche, Bodes Well For Combinations

New cancer immunotherapies are doing well in lung cancer, with Merck's Keytruda picking up share in the first-line setting and Roche's Tecentriq in second-line. Bristol-Myers Squibb is banking on combo therapy to restore its momentum.

Topic immuno-oncology

Scrip

Therapeutic Progress Amid Political Turbulence: Could 2017 Be Pharma's Year?

12 Dec 2016

Therapeutic Progress Amid Political Turbulence: Could 2017 Be Pharma's Year?

Delivering clinical advances in areas including immuno-oncology and Alzheimer's disease data while navigating the stormy seas of global politics could represent an opportunity for pharma to influence change. An uptick in sector M&A could also ensue if Trump offers US corporations a tax holiday.

Topic immuno-oncology

Scrip

Merck's Keytruda Chemo-Combo Data Has Big Implications For Future Of Immuno-Oncology

By Jessica Merril 10 Oct 2016

Merck's Keytruda Chemo-Combo Data Has Big Implications For Future Of Immuno-Oncology

Merck’s strong Phase II data testing Keytruda with chemotherapy

Topic immuno-oncology

Biomedtracker

​Analyzing ASCO 2016

13 Jun 2016

Topic immuno-oncology

Datamonitor Healthcare

Need help entering the Ulcerative Colitis market?

13 Sep 2015

Need help entering the Ulcerative Colitis market?

Entering an established market as a new player can be daunting. Often it's difficult to know exactly where you should be targeting your trial, and also what patient group you should be targeting your treatment at.

Topic immuno-oncology

Next steps

Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.

Request live demo now:

Our team is ready to hear from you for a particular request or area of interest. Please do not hesitate to reach out and discuss.

Contact us for product technical and account support.

  • US Toll-Free   : +1 888 670 8900 
  • US Toll             : +1 212-600-3520
  • UK & Europe : +44 (0) 208 052 0700

Have an immediate and specific information need?

Browse and buy from 1000s of analysis and research reports now: